Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Interim report 2023/24 - Full-year guidance maintained despite continued challenging market conditions | ||
By: GlobeNewswire - 05 Feb 2024 | Back to overview list |
|
ANNOUNCEMENT NO. 249 5 February 2024 Interim report for the first half of 2023/24 Full-year guidance maintained despite continued challenging market conditions Rasmus Kofoed, CEO: “Rasmus Kofoed, CEO: “In the second quarter, we saw early signs of market conditions improving within our key market area, cell-based therapy, but the investment climate remains subdued. Our revenue therefore continued to be under pressure, as expected, declining 15% year-on-year to DKK 108.1 million. Lower sales of instruments remained a drag on revenue, whereas sales of consumables and services both showed satisfactory growth. In the first half of 2023/24, our sales initiatives were maintained at a high level with the aim of identifying new customers and generating additional sales to existing customers. Furthermore, we have focused strongly on planning the roll-out of our new XcytoMatic products to wider customer groups. We are seeing growing interest in our new XcytoMatic 40 (XM40) and XcytoMatic 30 (XM30) instruments. Combined with a strong underlying business and further product launches scheduled in 2024, this makes me confident that we will see gradual progress in the second half, while at the same time creating a solid platform for growth in the coming years. We therefore maintain our full-year revenue and EBITDA guidance”. Sales and operating results
Conference call The Company will host a conference call on Tuesday, 6 February at 11:00 a.m. Rasmus Kofoed, CEO, and Niels Høy Nielsen, CFO, will present the interim report for the first half of 2023/24. Their presentation will be followed by a Q&A session. The conference call will be conducted in English. Link to the conference call: H1 2023/24 webcast and conference call The interim report for the first half of 2023/24 is attached to this announcement. Additional information Rasmus Kofoed, CEO Niels Høy Nielsen, CFO Tel.: (+45) 25 51 87 24 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson. ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com
Attachment |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |